메뉴 건너뛰기




Volumn 71, Issue 6, 2013, Pages 1635-1643

Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors

Author keywords

CYP3A4; Esomeprazole; Ketoconazole; Pazopanib; Pharmacokinetics

Indexed keywords

ESOMEPRAZOLE; KETOCONAZOLE; PAZOPANIB;

EID: 84878626843     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2164-3     Document Type: Article
Times cited : (95)

References (17)
  • 1
    • 49449117755 scopus 로고    scopus 로고
    • Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2- pyrimidinyl]amino]-2-methyl-b enzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor
    • 18620382 10.1021/jm800566m 1:CAS:528:DC%2BD1cXosVGrtL4%3D
    • Harris PA, Boloor A, Cheung M et al (2008) Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino] -2-methyl-b enzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem 51:4632-4640
    • (2008) J Med Chem , vol.51 , pp. 4632-4640
    • Harris, P.A.1    Boloor, A.2    Cheung, M.3
  • 2
    • 77949890945 scopus 로고    scopus 로고
    • Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial
    • 20100962 10.1200/JCO.2009.23.9764 1:CAS:528:DC%2BC3cXktF2lt78%3D
    • Sternberg CN, Davis ID, Mardiak J et al (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28:1061-1068
    • (2010) J Clin Oncol , vol.28 , pp. 1061-1068
    • Sternberg, C.N.1    Davis, I.D.2    Mardiak, J.3
  • 3
    • 84861098484 scopus 로고    scopus 로고
    • Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial
    • 22595799 10.1016/S0140-6736(12)60651-5
    • van der Graaf WT, Blay JY, Chawla SP et al (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379:1879-1886
    • (2012) Lancet , vol.379 , pp. 1879-1886
    • Van Der Graaf, W.T.1    Blay, J.Y.2    Chawla, S.P.3
  • 5
    • 77958498524 scopus 로고    scopus 로고
    • An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5 + 1 cocktail in patients with advanced solid tumors
    • 20881954 10.1038/clpt.2010.158 1:CAS:528:DC%2BC3cXhtlWmurjL
    • Goh BC, Reddy NJ, Dandamudi UB et al (2010) An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5 + 1 cocktail in patients with advanced solid tumors. Clin Pharmacol Ther 88:652-659
    • (2010) Clin Pharmacol Ther , vol.88 , pp. 652-659
    • Goh, B.C.1    Reddy, N.J.2    Dandamudi, U.B.3
  • 6
    • 79952596398 scopus 로고    scopus 로고
    • Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects
    • 21395644 10.1111/j.1365-2125.2010.03845.x 1:CAS:528:DC%2BC3MXltVKrtL0%3D
    • Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D (2011) Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects. Br J Clin Pharmacol 71:522-527
    • (2011) Br J Clin Pharmacol , vol.71 , pp. 522-527
    • Abbas, R.1    Hug, B.A.2    Leister, C.3    Burns, J.4    Sonnichsen, D.5
  • 7
    • 4644287353 scopus 로고    scopus 로고
    • Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects
    • 15138710 10.1007/s00280-004-0832-z 1:CAS:528:DC%2BD2cXntV2htr0%3D
    • Dutreix C, Peng B, Mehring G, Hayes M, Capdeville R, Pokorny R, Seiberling M (2004) Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol 54:290-294
    • (2004) Cancer Chemother Pharmacol , vol.54 , pp. 290-294
    • Dutreix, C.1    Peng, B.2    Mehring, G.3    Hayes, M.4    Capdeville, R.5    Pokorny, R.6    Seiberling, M.7
  • 8
    • 77949369418 scopus 로고    scopus 로고
    • Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors
    • 20108303 10.1002/cncr.24927 1:CAS:528:DC%2BC3cXktFGgsLc%3D
    • Johnson FM, Agrawal S, Burris H et al (2010) Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer 116:1582-1591
    • (2010) Cancer , vol.116 , pp. 1582-1591
    • Johnson, F.M.1    Agrawal, S.2    Burris, H.3
  • 10
    • 0346734217 scopus 로고    scopus 로고
    • Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: A five-way crossover study
    • 14687806 10.1111/j.1572-0241.2003.08783.x 1:CAS:528:DC%2BD3sXpvVahs7o%3D
    • Miner P Jr, Katz PO, Chen Y, Sostek M (2003) Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 98:2616-2620
    • (2003) Am J Gastroenterol , vol.98 , pp. 2616-2620
    • Miner, Jr.P.1    Katz, P.O.2    Chen, Y.3    Sostek, M.4
  • 11
    • 77955807815 scopus 로고    scopus 로고
    • Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib
    • 20498287 10.1177/0091270009346061 1:CAS:528:DC%2BC3cXhtVCmsL3J
    • Yin OQ, Gallagher N, Fischer D, Demirhan E, Zhou W, Golor G, Schran H (2010) Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. J Clin Pharmacol 50:960-967
    • (2010) J Clin Pharmacol , vol.50 , pp. 960-967
    • Yin, O.Q.1    Gallagher, N.2    Fischer, D.3    Demirhan, E.4    Zhou, W.5    Golor, G.6    Schran, H.7
  • 12
    • 80955128532 scopus 로고    scopus 로고
    • Risk of high-grade liver toxicity with pazopanib in patients with cancer: A meta-analysis
    • Kapadia S, Hapani S, Wu S (2011) Risk of high-grade liver toxicity with pazopanib in patients with cancer: a meta-analysis. J Clin Oncol 29(suppl):abstract 4595
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL. , pp. 4595
    • Kapadia, S.1    Hapani, S.2    Wu, S.3
  • 13
    • 0028357256 scopus 로고
    • Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole
    • 8181191 10.1038/clpt.1994.60 1:STN:280:DyaK2c3js1ynsA%3D%3D
    • Olkkola KT, Backman JT, Neuvonen PJ (1994) Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 55:481-485
    • (1994) Clin Pharmacol Ther , vol.55 , pp. 481-485
    • Olkkola, K.T.1    Backman, J.T.2    Neuvonen, P.J.3
  • 14
    • 10744232330 scopus 로고    scopus 로고
    • The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective
    • 12814957 10.1124/dmd.31.7.815 1:CAS:528:DC%2BD3sXltFalu70%3D
    • Bjornsson TD, Callaghan JT, Einolf HJ et al (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815-832
    • (2003) Drug Metab Dispos , vol.31 , pp. 815-832
    • Bjornsson, T.D.1    Callaghan, J.T.2    Einolf, H.J.3
  • 15
    • 78449297407 scopus 로고    scopus 로고
    • A phase i study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors
    • 20980999 10.1038/clpt.2010.199 1:CAS:528:DC%2BC3cXhsVegu7bE
    • Heath EI, Chiorean EG, Sweeney CJ et al (2010) A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors. Clin Pharmacol Ther 88:818-823
    • (2010) Clin Pharmacol Ther , vol.88 , pp. 818-823
    • Heath, E.I.1    Chiorean, E.G.2    Sweeney, C.J.3
  • 16
    • 0036024209 scopus 로고    scopus 로고
    • Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects
    • 12144580 10.1046/j.1365-2036.2002.01292.x 1:CAS:528:DC%2BD38XntVCjsrg%3D
    • Warrington S, Baisley K, Boyce M, Tejura B, Morocutti A, Miller N (2002) Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects. Aliment Pharmacol Ther 16:1301-1307
    • (2002) Aliment Pharmacol Ther , vol.16 , pp. 1301-1307
    • Warrington, S.1    Baisley, K.2    Boyce, M.3    Tejura, B.4    Morocutti, A.5    Miller, N.6
  • 17
    • 78249247114 scopus 로고    scopus 로고
    • The effects of dose and timing of esomeprazole administration on 24-h, daytime and night-time acid inhibition in healthy volunteers
    • 20955444 10.1111/j.1365-2036.2010.04469.x 1:CAS:528:DC%2BC3cXhsFanu7fF
    • Wilder-Smith C, Rohss K, Bokelund Singh S, Sagar M, Nagy P (2010) The effects of dose and timing of esomeprazole administration on 24-h, daytime and night-time acid inhibition in healthy volunteers. Aliment Pharmacol Ther 32:1249-1256
    • (2010) Aliment Pharmacol Ther , vol.32 , pp. 1249-1256
    • Wilder-Smith, C.1    Rohss, K.2    Bokelund Singh, S.3    Sagar, M.4    Nagy, P.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.